Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aptose Biosciences Inc. APTO
$0.50
+$0 (0.81%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
46428244.00000000
-
week52high
1.18
-
week52low
0.43
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.72647900
-
EPS
-0.51000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| RBC Capital | Outperform | Outperform | 10 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 21 дек 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 12 ноя 2021 г. |
| Oppenheimer | Outperform | Outperform | 24 мар 2021 г. |
| Maxim Group | Buy | 20 февр 2020 г. | |
| RBC Capital | Outperform | Outperform | 02 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Whitehead Warren | A | 100000 | 100000 | 19 янв 2023 г. |
| Seizinger Bernd R. | A | 100000 | 100000 | 19 янв 2023 г. |
| Vincent Mark D. | A | 100000 | 100000 | 19 янв 2023 г. |
| Rice William G. | A | 400000 | 400000 | 19 янв 2023 г. |
| Rice William G. | A | 513252 | 150000 | 19 янв 2023 г. |
| Payne Fletcher | A | 200000 | 200000 | 19 янв 2023 г. |
| Payne Fletcher | A | 100000 | 100000 | 19 янв 2023 г. |
| PLATZER ERICH | A | 100000 | 100000 | 19 янв 2023 г. |
| LEDRU PHILIPPE | A | 200000 | 200000 | 19 янв 2023 г. |
| LEDRU PHILIPPE | A | 100500 | 100000 | 19 янв 2023 г. |
Новостная лента
Aptose Biosciences Inc. (APTO) Q1 2023 Earnings Call Transcript
Seeking Alpha
08 мая 2023 г. в 21:22
Aptose Biosciences Inc. (NASDAQ:APTO ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Susan Pietropaolo – Corporate Communications & Investor Relations William G. Rice – Chairman, President and Chief Executive Officer Rafael Bejar – Senior Vice President and Chief Medical Officer Fletcher Payne – Senior Vice President and Chief Financial Officer Conference Call Participants Edward Tenthoff – Piper Sandler & Co. Li Watsek – Cantor Fitzgerald Joseph Pantginis – H.C.
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
GlobeNewsWire
04 мая 2023 г. в 07:01
SAN DIEGO and TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets 2023 Global Healthcare Conference on May 17, 2023.
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
GlobeNewsWire
24 апр 2023 г. в 07:01
SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the market, and provide a corporate update.
Aptose to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
GlobeNewsWire
10 апр 2023 г. в 16:01
SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel at Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference on April 20, 2023.
Aptose Biosciences Announces Q4 And FY 2022 Results
Pulse2
24 мар 2023 г. в 14:20
Aptose Biosciences (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, announced its financial results for the fourth quarter and year ended December 31, 2022, and provided a corporate update. The post Aptose Biosciences Announces Q4 And FY 2022 Results appeared first on Pulse 2.0.